Abstract
AbstractFatty acid synthesis (FAS) has been shown to play a key role in the survival of brain-metastatic (BM) breast cancer. We demonstrate that the fatty acid synthase inhibitor TVB-2640 synergizes with the topoisomerase inhibitor SN-38 in triple-negative breast cancer (TNBC) BM cell lines, upregulates FAS and downregulates cell cycle progression gene expression, and slows the motility of TNBC BM cell lines. The combination of SN-38 and TVB-2640 warrants further consideration as a potential therapeutic option in TNBC BMs.
Funder
Susan G. Komen
Breast Cancer Research Foundation
Publisher
Springer Science and Business Media LLC
Reference31 articles.
1. Mills, M. N. et al. Management of brain metastases in breast cancer: a review of current practices and emerging treatments. Breast Cancer Res. Treat. 180, 279–300 (2020).
2. Hosonaga, M., Saya, H. & Arima, Y. Molecular and cellular mechanisms underlying brain metastasis of breast cancer. Cancer Metastasis Rev. 39, 711–720 (2020).
3. Kadamkulam Syriac, A., Nandu, N. S. & Leone, J. P. Central nervous system metastases from triple-negative breast cancer: current treatments and future prospective. Breast Cancer (Dove Med Press) 14, 1–13 (2022).
4. Haddad-Tovolli, R., Dragano, N. R. V., Ramalho, A. F. S. & Velloso, L. A. Development and function of the blood-brain barrier in the context of metabolic control. Front. Neurosci. 11, 224 (2017).
5. Ngo, B. et al. Limited environmental serine and glycine confer brain metastasis sensitivity to PHGDH inhibition. Cancer Discov. 10, 1352–1373 (2020).